Chamie and coworkers analyzing the prognostic significance of comorbid diseases in a sample of 1,031 men diagnosed with non-metastatic prostate cancer between 1997 and 2004. 1 The detailed data allowed a comparison with our radical prostatectomy data set (2,205 patients treated between 1992 and 2005, mean follow-up 8.9 years), concerning the four comorbid conditions: lung disease, peripheral vascular disease and diabetes with or without end organ damage (Table 1) . With the exception of peripheral vascular disease (affecting only 2 % of patients in our sample), in men aged 65 years or older selected for radical prostatectomy, the 10-year competing mortality rates were lower than in the unselected sample analyzed by Chamie and coworkers, 1 and clearly below the 50 % limit. Among the few men with one of the four comorbidities selected for radical prostatectomy at an age of 75 years or older, no competing mortality was observed until now, probably due to the particular strict selection in this very old subgroup. These differences illustrate that the filtering during primary treatment choice modulates the prognostic significance of comorbidity. Comorbid conditions that may appear as contraindications to curative treatment in unselected patients may no longer do so after passing the initial filtering. Clinicians should keep this effect in mind when they consider comorbid diseases during the treatment decision process in men with non-metastatic prostate cancer. 
To the Editor:-We read with great interest the study by Chamie and coworkers analyzing the prognostic significance of comorbid diseases in a sample of 1,031 men diagnosed with non-metastatic prostate cancer between 1997 and 2004. 1 The detailed data allowed a comparison with our radical prostatectomy data set (2, 205 patients treated between 1992 and 2005, mean follow-up 8.9 years), concerning the four comorbid conditions: lung disease, peripheral vascular disease and diabetes with or without end organ damage (Table 1) . With the exception of peripheral vascular disease (affecting only 2 % of patients in our sample), in men aged 65 years or older selected for radical prostatectomy, the 10-year competing mortality rates were lower than in the unselected sample analyzed by Chamie and coworkers, 1 and clearly below the 50 % limit. Among the few men with one of the four comorbidities selected for radical prostatectomy at an age of 75 years or older, no competing mortality was observed until now, probably due to the particular strict selection in this very old subgroup. These differences illustrate that the filtering during primary treatment choice modulates the prognostic significance of comorbidity. Comorbid conditions that may appear as contraindications to curative treatment in unselected patients may no longer do so after passing the initial filtering. Clinicians should keep this effect in mind when they consider comorbid diseases during the treatment decision process in men with non-metastatic prostate cancer. 
